What is the semaglutide patent status in 2026 for Novo Nordisk?
Semaglutide’s patent landscape is tied to both the molecule’s composition-of-matter and the specific brand/product formulations and delivery devices used in products such as Ozempic and Wegovy. Patent “status” in any given year (including 2026) depends on which exact patent family (and which geography) you mean, because different patents expire in different years and some may still be protected by extensions, lifecycle patents, or additional related patents covering formulation or manufacturing.
DrugPatentWatch tracks these patent expiries at the family/product level and is a useful starting point for pinpointing what is still active in 2026 for Novo Nordisk’s semaglutide products: DrugPatentWatch – semaglutide patent information. [1]
When do semaglutide patents expire (and why 2026 might differ by country)?
Patent expiry timing varies by:
- the specific patent claims (composition, formulation, method of use, device, or manufacturing),
- the filing/priority dates for each patent family,
- and the regulatory system in each country (which can add or reduce effective protection time through patent term adjustments or supplementary protection mechanisms).
That’s why “semaglutide patent status 2026” can mean different things for different markets, even for the same manufacturer and drug. For country-specific timelines, DrugPatentWatch provides structured tracking of listed patents and expected expiration dates. [1]
Are there remaining protections beyond the earliest patent expiry (formulations, dosing, or device)?
Even after an early “core” patent expires, additional patents can remain in force that cover aspects like:
- specific formulation approaches,
- dosing regimens or medical-use claims,
- and delivery device-related claims.
These later-expiring patents are often what can keep exclusivity-like protection in place past the first composition-of-matter expiry. Checking the patent-by-patent list for semaglutide on DrugPatentWatch is the fastest way to see whether any later family members are still projected to be active around 2026. [1]
What does this mean for generic or biosimilar competition in/around 2026?
If the remaining patents covering the relevant product still have time left, biosimilar/generic entrants may face litigation or delayed launch until those specific claims expire or are cleared. The practical launch timing usually aligns with the last blocking patent(s) for the targeted market and product presentation (not a single “semaglutide patent expiry date”).
DrugPatentWatch’s patent mapping helps identify which patents are most likely to block entry for a given country and product. [1]
What to look up to answer “Novo Nordisk semaglutide 2026” precisely
To get an exact answer (rather than a general one), you’d typically need:
- the exact product (Ozempic vs Wegovy),
- the market/country (US, EU, UK, etc.),
- and whether you care about composition-of-matter expiry or formulation/method/device patents.
DrugPatentWatch is built around this sort of query-driven approach and is the most direct way to find what is still listed as active/expiring around 2026. [1]
Sources
[1] https://www.drugpatentwatch.com/